ClinicalTrials.gg
TerminatedNCT04469725Updated Mar 12, 2024

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

A Phase 2 interventional study of KN046 in Thymic Carcinoma, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 2, Interventional, and Treatment

Why this study was terminated
The termination of this study does not involve safety issues. The overall safety of KN046 is good, and no new safety signals have been found. The decision to terminate this study was made due to the adjustment of the sponsor's development strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Thymoma with a site in China — 17 open to participants now, 18 under way, 3 of them phase 3. Thymoma · China.

Enrollment
13th of 31
95 · median 64
Started
2020
with 3 others
Phase 2
12 of 36
7 open now
Registered
11th of 36
by date

Among the 36 studies in Thymoma with a site in China, this one is the 13th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2020, is one of 12 in phase 2, and was the 11th registered.

Thymoma

133 studies on the registry are indexed under Thymoma; 37 are open to participants now.

Browse Thymoma studies →

Open to participants now

17 of the 36 studies in Thymoma with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Thymoma studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Thymoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, multi-center, single arm study in subjects with advanced thymic carcinoma after failure of platinum-based combination chemotherapy. Subjects should have documented progressive disease while on platinum-based combination chemotherapy. If subjects discontinued platinum-based therapy due to reasons other than progressive disease, subjects should have completed at least 2 cycles of platinum-based combination chemotherapy before the commencement of documented progressive disease. Subjects will be treated with KN046 5 milligram per kilogram every 2 weeks.

03

Conditions studied

  • Thymic Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ≥18 years
  • confirmed diagnosis of thymic carcinoma
  • Inoperable or disease
  • Had failed at least one regimen containing platinum-based combination chemotherapy for locally advanced unresectable or metastatic disease
  • Baseline

Exclusion criteria

Exclusion Criteria

  • Thymomas, thymolipoma, germ cell tumors, teratomas, seminomas
  • or untreated active CNS (central nervous system) or leptomeningeal metastasis.
  • Is currently participating and receiving an drug or has participated in a study of an investigational drug within 4 weeks
  • Has received other anti-tumor treatment within 4 weeks
  • Major surgery for any reason, except diagnostic , within 4 weeks of the first administration of trial treatment
  • Curative radiation within 3 months of the first dose of trial treatment.
  • Subjects receiving agents (such as ) for any reason should be tapered off these drugs before initiation of trial treatment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Thymic carcinoma

    enrolled subjects will receive KN046 every 2 weeks.

    Drug: KN046

Interventions

  • DrugKN046

    KN046 5 milligram per kilogram, every 2 weeks

06

What researchers measure

Primary outcomes

  1. ORR

    ORR (best overall response) per RECIST v1.1 calculated as the proportion of subjects with a best overall response defined as confirmed complete response or confirmed partial response (CR+PR) by Independent Review Committee;

    Time frame: up to 2 years

Secondary outcomes

  1. DOR

    DOR (duration of response), calculated as the time from the date of the first documented CR or PR to the first documented progression or death due to underlying cancer;

    Time frame: up to 3 years

  2. DCR

    DCR (disease control rate), calculated as the proportion of subjects with best overall response of CR, PR, or SD (stable disease);

    Time frame: up to 3 years

  3. CBR

    CBR (clinical benefit rate), calculated as the proportion of subjects with best overall response of CR, PR, or SD on at least 24 weeks;

    Time frame: up to 3 years

  4. PFS

    PFS (progression free survival), defined as time from first dose of trial treatment to progression or death due to any cause;

    Time frame: up to 3 years

  5. TTR

    TTR (time to response), calculated as the time from first dose of trial treatment to first documented response (CR+PR);

    Time frame: up to 3 years

07

Study locations

1 site
  • Shanghai Chest Hospital
    Shanghai, Shanghai 200030, China
08

References and documents

Publications

  • Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. PubMed 34393061 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jul 2023, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 14, 2020
StartActual
Dec 2, 2020
Primary completionActual
Jul 7, 2023
CompletionActual
Jul 7, 2023
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04469725
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Dec 2, 2020
Primary completion
Jul 7, 2023
Completion
Jul 7, 2023
Last update
Mar 12, 2024

Study contacts

Xiaolong Fu, MD
principal investigator · Shanghai Chest Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Erfonrilimab

Start the discussion